|
|
Vol. 12.13 – 20 July, 2026
|
|
|
|
|
|
|
|
|
Investigators identified a previously underappreciated Gli2–Serpinh1 regulatory axis that plays a key role in fibroblast state transitions during skin wound healing. [NPJ Regenerative Medicine]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
DERMAL STEM CELLS & TISSUE REGENERATION
|
|
|
|
|
|
Researchers identified dermal papillary fibroblasts as drivers of persistent granulation tissue formation in junctional epidermolysis bullosa, revealing TGFβ signaling as a promising therapeutic target.
[EMBO Molecular Medicine]
|
|
|
|
|
|
Scientists showed that ATP6V1A protects against UVB-induced skin cell senescence by preserving lysosomal function and autophagy, identifying a potential target for combating photoaging.
[Biology Direct]
|
|
|
|
|
|
Researchers showed that targeting PRMT5 suppresses psoriasis by destabilizing p65 and dampening inflammatory signaling in keratinocytes.
[Molecular Medicine]
|
|
|
|
|
|
The authors used a three-dimensional skin model to study how CD14+ monocytes, M1 and M2-like macrophages induce fibroblasts activation and contraction in collagen type I hydrogels.
[Scientific Reports]
|
|
|
|
|
|
Scientists aimed to construct a basic fibroblast growth factor (bFGF)-glycosylphosphatidylinositol-anchored exosome system (ADSC-Exo-bFGF) and further explore its therapeutic efficacy and underlying molecular mechanisms in skin wound healing. [Journal of Molecular Histology]
|
|
|
|
|
|
|
|
The authors highlight how senolytic and senomorphic therapies target cellular senescence to reduce skin aging and fibrosis, advancing new regenerative and aesthetic dermatology strategies.
[GeroScience]
|
|
|
|
|
|
Investigators discuss the biological roles of keratinocytes and fibroblasts in skin homeostasis and wound repair, focusing on their crosstalk that regulate inflammation, extracellular matrix remodeling, angiogenesis, and re-epithelialization. [Molecular Biology Reports]
|
|
|
|
|
|
|
|
|
Alpha Tau Medical Ltd. announced the successful treatment of the first patient in the ADMIRE, a clinical trial evaluating intratumoral Alpha DaRT for immunocompromised patients with recurrent cutaneous squamous cell carcinoma.
|
|
|
|
|
|
|
|
September 15-17, 2026 Boston, Massachusetts, United States
|
|
|
|
|
|
|
|
|
|
|
The Medical College of Wisconsin – Milwaukee, Wisconsin, United States
|
|
|
|
|
|
|
University of Pennsylvania – Philadelphia, Pennsylvania, United States
|
|
|
|
|
|
|
UmeÃ¥ University – UmeÃ¥, Sweden
|
|
|
|
|
|
|
French National Institute for Health Research – Lyon, France
|
|
|
|
|
|
|
University of Arizona Cancer Center – Tucson, Arizona, United States
|
|
|
|
|
|